A recent study demonstrated that the combination of ribociclib and a nonsteroidal aromatase inhibitor notably enhanced invasive disease-free survival in patients with stage II or III early breast cancer, both HER2-positive and HER2-negative [82]. Here, CYP19A1 is linked to breast carcinoma.